PhD in industrial organic chemistry awarded at the University of Florence, Italy, in 2006. More than 15 years experience in the field of vaccines development, focusing her research on bacterial vaccines against AMR pathogens mainly affecting impoverished communities. Involved in the development of vaccines against Salmonella Typhi, Salmonella Paratyphi A, non-typhoidal Salmonella, Shigella, Group A Streptococcus, klebsiella pneumoniae and Neisseria meningitidis. From 2020, she is Senior Project Leader for the Shigella project at GSK Vaccines Institute for Global Health (Siena, Italy) and now also Director of the Innovation Academy, working on innovative technology platforms for vaccine development. Over the years she has acquired great expertise on glycoconjugation and Generalised Modules for Membrane Antigens (GMMA) platforms. Author of more than 80 scientific publications and several patent applications, she has many collaborations in place with academic and industrial partners. Board member of the MRC-funded BactiVac, the first bacterial vaccine network, with a LMIC-centric focus.
A holistic approach will be integral to tackling the AMR pandemic – how is industry ensuring the development of new tools & which interventions are best suited to our priority pathogens?